Rare Anaemias, Sickle-Cell Disease and COVID-19
Main Article Content
Keywords
.
Abstract
For rare haematological diseases (RHD), the first question to be answered is if patients with be- nign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor.
Downloads
Metrics
References
2. European Commission. Health and Food Safety Directorate General. “COVID.19 Clinical Management Support System”. e-News. 27/03/2020. https://www.vml.org/enews-march-27-2020/.
3. COVID-19 and Rare Diseases. Orphanews 27 of March 2020. https://www.drroyspencer.com/2020/03/covid-19-deaths-in-europe-excess-mortality-is-down/.
4. COVID-19 and Rare Hematological Diseases. EuroBloodNet https://eurobloodnet.eu/covid-19/.
5.Thalassemia International Federation .The COVID–19 pandemic and haemoglobin disorders. A contribution of Thalassaemia International Federation to its global patients’ community.
https://thalassaemia.org.cy/publications/tif-publications/a-tif-proposed-haemoglobinopathy-patient-pathway-during-the-covid-19-pandemic-2.
6. . Haemoglobinopathy Co-ordinating Centres. https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f05/.
Article Sidebar
Article Details
How to Cite
NOTICE TO AUTHORS - Copyrights
The Authors confirm that neither the manuscript nor any part of it has been published or is under consideration for publication elsewhere. The same Authors assign all rights, including but no limiteded to the copyright, for the present manuscript to Acta Biomedica upon its acceptance for publication. When the manuscript is accepted, the Editorial office of Acta Biomedica inform about the Author reported in the manuscript . If no reply will be received, Acta Biomedica Editorial office will apply the rule “no response means implied consent” and it will proceed with the publication.
Accepted papers become the permanent property of ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA and no part may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of both the author and the publisher.